370 related articles for article (PubMed ID: 18641546)
1. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
4. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.
Heller T; van Gelder T; Budde K; de Fijter JW; Kuypers D; Arns W; Schmidt J; Rostaing L; Powis SH; Claesson K; Macphee IA; Pohanka E; Engelmayer J; Brandhorst G; Oellerich M; Armstrong VW
Am J Transplant; 2007 Jul; 7(7):1822-31. PubMed ID: 17532750
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
[TBL] [Abstract][Full Text] [Related]
8. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients.
González-Roncero FM; Govantes MA; Chaves VC; Palomo PP; Serra MB
Transplant Proc; 2007 Sep; 39(7):2176-8. PubMed ID: 17889129
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
[TBL] [Abstract][Full Text] [Related]
10. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
[TBL] [Abstract][Full Text] [Related]
11. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
12. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.
Roan JN; Chou CH; Hsu CH; Wu SY; Huang YC; Yang YJ; Luo CY
Ann Transplant; 2013 Feb; 18():43-52. PubMed ID: 23792500
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
[TBL] [Abstract][Full Text] [Related]
14. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
[TBL] [Abstract][Full Text] [Related]
15. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
Patel CG; Harmon M; Gohh RY; Akhlaghi F
Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
[TBL] [Abstract][Full Text] [Related]
16. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
17. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
[TBL] [Abstract][Full Text] [Related]
18. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
[TBL] [Abstract][Full Text] [Related]
19. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
[TBL] [Abstract][Full Text] [Related]
20. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
